BioSpace News Archive

NeoImmuneTech, Inc. today announced that the first patient has been dosed in a Phase 1b study of its lead drug candidate, NT-I7 (efineptakin alfa), a novel long-acting human interleukin-7 (IL-7), following CAR-T cell therapy tisagenlecleucel (Kymriah®) in patients with relapsed/refractory (r/r) Large B-Cell Lymphoma (LBCL).

XORTX Therapeutics Inc. announces the pricing of an underwritten public offering of 2,906,000 units (“Units”), with each Unit consisting of one common share, no par value, and one warrant (“Warrant”) to purchase one common share at a public offering price of US$4.13 per unit

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, presented today final data from the Phase II trial SATEEN on vafidemstat’s ability to reduce the inflammatory response in multiple sclerosis (MS) patients.

Poseida Therapeutics, Inc. today announced appointments to new roles on its executive leadership team.

GlobalLogic Inc. , a Hitachi Group Company and leader in Digital Engineering, today announced that it has been selected by Inspira Technologies to develop an algorithm-enhanced digital platform powering the ART device

Horizon Therapeutics plc (Nasdaq: HZNP) today announced results from a new analysis of the UPLIZNA pivotal Phase 2/3 N-MOmentum trial indicating a correlation between the depth of B-cell depletion and improved NMOSD patient outcomes.

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced the time of its third quarter 2021 earnings release and conference call.

Pear Therapeutics, Inc. today announced MassHealth, Massachusetts’ Medicaid program, has notified Pear of its intent to cover Pear’s prescription digital therapeutics (PDTs) reSET® and reSET-O® to fight the growing substance and opioid addiction crisis.

TC BioPharm LTD, a clinical stage biotechnology company developing an allogeneic gamma-delta T cell platform, today announces launch of a Phase I/II trial in COVID-19 infected patients in the UK.

Veru Inc. (NASDAQ: VERU), today announced that it has enrolled the first patient in its Phase 3 ARTEST registration trial of enobosarm.